Bifunctional Molecules Inhibit HIV Entry via Ternary Complex Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-based therapeutics for HIV infection face challenges such as severe side effects, lack of oral bioavailability, and high cost, and existing methods struggle to effectively recruit antibodies to target HIV due to its unique structural characteristics.
Innovation Solution
Development of bifunctional molecules that bind to the HIV glycoprotein gp120 and recruit anti-DNP antibodies, forming a ternary complex to inhibit viral entry and enhance immune recognition, thereby targeting HIV-infected cells for destruction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-based therapeutics are used to treat HIV infection, then immune-mediated destruction of HIV-infected cells is achieved, but severe side effects and high cost occur
Solution Approach 1:
The patent uses a small molecule compound as an intermediary that bridges HIV-infected cells and endogenous antibodies. The compound contains an antibody-binding domain that recruits endogenous antibodies and a HIV-binding domain that targets HIV-infected cells, creating a ternary complex that mediates immune destruction without requiring direct administration of therapeutic antibodies
Solution Approach 2:
The invention leverages the patient's own endogenous antibodies (particularly anti-DNP antibodies that naturally exist in many patients) to fight HIV infection. By recruiting these self-existing antibodies through the small molecule compound, the system uses the body's own immune resources rather than requiring external antibody therapy
2Reliability
If therapeutic antibodies are administered to target HIV, then HIV-infected cells are destroyed, but oral bioavailability is lacking
Solution Approach 1:
The patent creates a small molecule compound that copies or mimics the function of therapeutic antibodies by recruiting endogenous antibodies. Instead of administering large protein antibodies that cannot be orally bioavailable, a small molecule surrogate is used that achieves the same therapeutic effect through antibody recruitment
Solution Approach 2:
The small molecule compound serves as a temporary recruiter that brings together endogenous antibodies and HIV-infected cells. The compound itself is short-lived and metabolized, but it activates the longer-lasting endogenous antibody system that continues to provide therapeutic effect
3Reliability
If traditional antibody-based therapeutics are used to combat HIV, then immune destruction is achieved, but high cost is incurred
Solution Approach 1:
The system uses the patient's own endogenous antibodies (particularly anti-DNP antibodies present in many individuals) to provide therapeutic effect, eliminating the need to manufacture and administer expensive therapeutic antibodies. The small molecule compound is significantly cheaper to produce than protein-based antibody therapies
Solution Approach 2:
The small molecule compound replicates the function of expensive therapeutic antibodies at a fraction of the cost. By creating a molecular surrogate that recruits endogenous antibodies, the system achieves antibody-mediated immunity without the high manufacturing costs of biologic antibody products
4Reliability
If antibodies are used to bind HIV surface proteins, then viral neutralization is achieved, but HIV structural characteristics prevent effective epitope binding
Solution Approach 1:
The small molecule compound acts as an intermediary that overcomes HIV's structural defenses. The compound's HIV-binding domain penetrates or bypasses the viral envelope protein structure to reach and bind gp120, while the antibody-binding domain recruits antibodies that can then effectively neutralize the virus despite HIV's epitope spacing challenges
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bifunctional molecules effectively inhibit HIV entry into cells, reduce the likelihood of infection, and provide a cost-effective, immunogenicity-low alternative to traditional antibody-based therapies by leveraging existing anti-DNP antibodies in the bloodstream.
Implementation Method 1
bifunctional molecules that bind to the HIV glycoprotein gp120
Implementation Method 2
recruit anti-DNP antibodies, forming a ternary complex to inhibit viral entry and enhance immune recognition
Data Source
AI summary
The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as ARM-HI's, function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by recruiting anti-DNP antibodies to gp120-expressing cells, thereby preventing cell infection and spread of HIV. It has been shown that ARM-HI's bind to gp120 and gp-120 expressing cells competitively with CD4, thereby decreasing viral infectivity as shown by an MT-2 cell assay, the binding leading to formation of a ternary complex by recruiting anti-DNP antibodies to bind thereto, the antibodies present in the ternary complex promoting the complement-dependent destruction of the gp120-expressing cells. Compounds and methods are described herein.